On June 1, 2014 (Taipei) TS-1 Capsule (Taiwan Capsule), a chemotherapeutic drug from Taiwan’s Toyo Pharmaceutical (4105: TW), reported that it has recently been listed in the "National Health Insurance Drug Benefits Project" after receiving an indication for advanced pancreatic cancer in August 2013 (Press release, TTY Biopharm, JUN 1, 2014, View Source;ai-si-mo—-huo-wan-ji-yi-zang-ai-zhi-jian-bao-gei-fu [SID1234526668]). The payment standard jointly drafted the resolution of the meeting and agreed to include the national health insurance drug payment. The payment was made to patients who were unable to undergo surgical resection or metastatic pancreatic cancer in the late stage of treatment, and took effect on June 1, 2014. TS-1 Capsule was originally developed by Japan Dapeng Pharmaceutical Industry Co., Ltd. and was authorized to develop and market this drug in Taiwan’s Toyo Pharmaceuticals in Taiwan.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Taiwanese pancreatic cancer has shown significant growth in recent years. According to the latest data released by the Department of Health and Welfare, there were 1,827 new patients with pancreatic cancer in the 100 years of the Republic of China, and 1,607 patients died of pancreatic cancer, which ranks among the top ten causes of cancer in the country. Eight people ranked a little more than 99 years ago in the Republic of China, showing that the current treatment is not effective. Most pancreatic cancers are diagnosed at the late stage when the tumor cannot be surgically removed. The patient needs to receive systemic chemotherapy. However, the survival time of advanced pancreatic cancer is extremely short, and the choice of drugs is limited, and patients need urgently more effective treatment options.
Mr. Lin Rongjin, General Manager of Taiwan’s Toyo Pharmaceutical Co., Ltd., said: "Continuously cultivating medicines in the field of cancer has always been the goal of Taiwan’s East Sample. This breakthrough will benefit more cancer patients. It is a good news." Taiwan’s Toyo Pharmaceutical Co., Ltd. and Japan’s Dapeng Pharmaceutical Co., Ltd. Phase III clinical trials of pancreatic cancer in Taiwan and Japan are the largest clinical studies of pancreatic cancer in Asia at present. They include Taiwan University, Chang Gung, Wing, Ma, China, Changji, Chengda, Chi Mei , Gao Yi attached medical doctors have joined this clinical study. The results of this study confirm that oral TS-1 (Evans) has comparable efficacy to current standard gemcitabine in the treatment of advanced pancreatic cancer and has lower blood side effects; if combined with gemcitabine treatment, it can prolong the time of disease progression and can be effective. Reduce the tumor and relieve the clinical symptoms caused by the tumor. This research result of advanced pancreatic cancer was published in May 2013 in the internationally renowned journal Journal of Clinical Oncology. Taiwan now offers advanced and effective new treatment options for patients with advanced pancreatic cancer. Each year, it benefits about 1,500 patients with advanced pancreatic cancer.